角膜作为测试基于结缔组织生长因子的抗瘢痕药物的模型。
Cornea As a Model for Testing CTGF-Based Antiscarring Drugs.
作者信息
Sriram Sriniwas, Tran Jennifer A, Zieske James D
机构信息
Schepens Eye Research Institute, Boston, MA, USA.
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
出版信息
Bone Tissue Regen Insights. 2016 Jan-Dec;7. doi: 10.4137/BTRI.S19954. Epub 2016 Jun 20.
Scarring remains a serious complication of the wound healing process that can lead to the formation of excessive fibrous connective tissue in an organ or tissue leading to pain and loss of function. This process is mainly regulated by Transforming growth factor β1 (TGF-β1), which binds to receptors and induces its downstream mediator, Connective tissue growth factor (CTGF). The number of drugs targeting CTGF for treating scars has been on the rise in the past few years. The purpose of this article is to suggest the possibility of using cornea as a model for testing anti-CTGF therapies for scarring.
瘢痕形成仍然是伤口愈合过程中的一个严重并发症，它会导致器官或组织中形成过多的纤维结缔组织，从而引起疼痛和功能丧失。这个过程主要由转化生长因子β1（TGF-β1）调节，TGF-β1与受体结合并诱导其下游介质结缔组织生长因子（CTGF）。在过去几年中，靶向CTGF治疗瘢痕的药物数量一直在增加。本文的目的是提出将角膜作为测试抗CTGF瘢痕治疗方法的模型的可能性。
Zotero 插件